IBO
Impact BioMedical Inc.
Biotechnology
Market Cap$148M
5Y Perf.-99.8%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
IBO vs NNVC
Revenue, margins, valuation, and 5-year total return — side by side.
NNVC
NanoViricides, Inc.
Biotechnology
Market Cap$32M
5Y Perf.+39.0%
IBO vs NNVC — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | IBO | NNVC |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $148M | $32M |
| Revenue (TTM) | $0.00 | $0.00 |
| Net Income (TTM) | $-25M | $-2.22T |
| Gross Margin | 100.0% | — |
| Operating Margin | 23.7% | — |
| Total Debt | $9M | $0.00 |
| Cash & Equiv. | $2M | $2M |
IBO vs NNVC — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
IBO
NNVC
| Stock | May 23 | May 26 | Return |
|---|---|---|---|
| Impact BioMedical I… (IBO) | 100 | 0.2 | -99.8% |
| NanoViricides, Inc. (NNVC) | 100 | 139.0 | +39.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: IBO vs NNVC
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: NNVC leads in 3 of 6 categories, making it the strongest pick for profitability and margin quality and recent price momentum and sentiment. Impact BioMedical Inc. is the stronger pick specifically for growth and revenue expansion and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
IBO
Impact BioMedical Inc.
The Income Pick
IBO is the clearest fit if your priority is income & stability and sleep-well-at-night.
- Dividend streak 1 yrs, beta 0.12
- Lower volatility, beta 0.12, current ratio 0.25x
- Beta 0.12, current ratio 0.25x
Best for: income & stability and sleep-well-at-night
NNVC
NanoViricides, Inc.
The Growth Play
NNVC carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- EPS growth 10.0%
- -95.5% 10Y total return vs IBO's -97.5%
- 1.4% margin vs IBO's -88.0%
Best for: growth exposure and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | IBO | -6.2% revenue growth vs NNVC's -258K% |
| Quality / Margins | NNVC | 1.4% margin vs IBO's -88.0% |
| Stability / Safety | IBO | Beta 0.12 vs NNVC's 1.34 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | NNVC | +15.9% vs IBO's +4.1% |
| Efficiency (ROA) | NNVC | -18.1% ROA vs IBO's -124.8%, ROIC -114.0% vs 1.5% |
IBO vs NNVC — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLNNVCLAGGINGIBO
IBOImpact BioMedical Inc.
0leads
NNVCNanoViricides, Inc.
4leads
6 Total Categories
CATEGORYLEADERvs IBOMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
NNVC1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
NNVC4/7
Total Returns1Y, 3Y, 5Y total returns with dividends
NNVC5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
NNVC1/1
Income & Cash Flow (Last 12 Months)
NNVC leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
IBO and NNVC operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | IBOImpact BioMedical… | NNVCNanoViricides, In… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $0 |
| EBITDAEarnings before interest/tax | -$28M | -$8M |
| Net IncomeAfter-tax profit | -$25M | -$2.22T |
| Free Cash FlowCash after capex | -$3M | -$3.73T |
| Gross MarginGross profit ÷ Revenue | +100.0% | — |
| Operating MarginEBIT ÷ Revenue | +23.7% | — |
| Net MarginNet income ÷ Revenue | -88.0% | — |
| FCF MarginFCF ÷ Revenue | -168.1% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | -19.5% | +21.4% |
NNVC leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — IBO and NNVC each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | IBOImpact BioMedical… | NNVCNanoViricides, In… |
|---|---|---|
| Market CapShares × price | $148M | $32M |
| Enterprise ValueMkt cap + debt − cash | $153M | $30M |
| Trailing P/EPrice ÷ TTM EPS | -86.28x | -2.32x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 231.79x | — |
| Price / SalesMarket cap ÷ Revenue | 86.06x | — |
| Price / BookPrice ÷ Book value/share | 27.72x | 2.94x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — IBO and NNVC each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
NNVC leads this category, winning 4 of 7 comparable metrics.
Profitability & Efficiency
NNVC delivers a -20.1% return on equity — every $100 of shareholder capital generates $-20 in annual profit, vs $-4 for IBO. On the Piotroski fundamental quality scale (0–9), IBO scores 4/9 vs NNVC's 1/9, reflecting mixed financial health.
| Metric | IBOImpact BioMedical… | NNVCNanoViricides, In… |
|---|---|---|
| ROE (TTM)Return on equity | -3.7% | -20.1% |
| ROA (TTM)Return on assets | -124.8% | -18.1% |
| ROICReturn on invested capital | +1.5% | -114.0% |
| ROCEReturn on capital employed | +2.6% | -101.1% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 1 |
| Debt / EquityFinancial leverage | 1.23x | — |
| Net DebtTotal debt minus cash | $7M | -$2M |
| Cash & Equiv.Liquid assets | $2M | $2M |
| Total DebtShort + long-term debt | $9M | $0 |
| Interest CoverageEBIT ÷ Interest expense | -21.60x | — |
NNVC leads this category, winning 4 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
NNVC leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in NNVC five years ago would be worth $4,022 today (with dividends reinvested), compared to $16 for IBO. Over the past 12 months, NNVC leads with a +15.9% total return vs IBO's +4.1%. The 3-year compound annual growth rate (CAGR) favors NNVC at 4.5% vs IBO's -88.2% — a key indicator of consistent wealth creation.
| Metric | IBOImpact BioMedical… | NNVCNanoViricides, In… |
|---|---|---|
| YTD ReturnYear-to-date | +22.4% | +20.7% |
| 1-Year ReturnPast 12 months | +4.1% | +15.9% |
| 3-Year ReturnCumulative with dividends | -99.8% | +14.1% |
| 5-Year ReturnCumulative with dividends | -99.8% | -59.8% |
| 10-Year ReturnCumulative with dividends | -97.5% | -95.5% |
| CAGR (3Y)Annualised 3-year return | -88.2% | +4.5% |
NNVC leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — IBO and NNVC each lead in 1 of 2 comparable metrics.
Risk & Volatility
IBO is the less volatile stock with a 0.12 beta — it tends to amplify market swings less than NNVC's 1.34 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NNVC currently trades 65.5% from its 52-week high vs IBO's 32.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | IBOImpact BioMedical… | NNVCNanoViricides, In… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.12x | 1.34x |
| 52-Week HighHighest price in past year | $1.95 | $2.23 |
| 52-Week LowLowest price in past year | $0.36 | $0.85 |
| % of 52W HighCurrent price vs 52-week peak | +32.6% | +65.5% |
| RSI (14)Momentum oscillator 0–100 | 50.8 | 67.0 |
| Avg Volume (50D)Average daily shares traded | 4.5M | 247K |
Evenly matched — IBO and NNVC each lead in 1 of 2 comparable metrics.
Analyst Outlook
NNVC leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
| Metric | IBOImpact BioMedical… | NNVCNanoViricides, In… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 1 | 2 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
NNVC leads this category, winning 1 of 1 comparable metric.
Key Takeaway
NNVC leads in 4 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 2 categories are tied.
Best OverallNanoViricides, Inc. (NNVC)Leads 4 of 6 categories
Loading custom metrics...
IBO vs NNVC: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Which is the better long-term investment — IBO or NNVC?
Over the past 5 years, NanoViricides, Inc.
(NNVC) delivered a total return of -59. 8%, compared to -99. 8% for Impact BioMedical Inc. (IBO). Over 10 years, the gap is even starker: NNVC returned -95. 5% versus IBO's -97. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
02Which is safer — IBO or NNVC?
By beta (market sensitivity over 5 years), Impact BioMedical Inc.
(IBO) is the lower-risk stock at 0. 12β versus NanoViricides, Inc. 's 1. 34β — meaning NNVC is approximately 973% more volatile than IBO relative to the S&P 500.
03Which is growing faster — IBO or NNVC?
On earnings-per-share growth, the picture is similar: NanoViricides, Inc.
grew EPS 10. 0% year-over-year, compared to 0. 0% for Impact BioMedical Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
04Which has better profit margins — IBO or NNVC?
NanoViricides, Inc.
(NNVC) is the more profitable company, earning 0. 0% net margin versus -88. 0% for Impact BioMedical Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IBO leads at 23. 7% versus 0. 0% for NNVC. At the gross margin level — before operating expenses — IBO leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — IBO or NNVC?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is IBO or NNVC better for a retirement portfolio?
For long-horizon retirement investors, Impact BioMedical Inc.
(IBO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 12)). Both have compounded well over 10 years (IBO: -97. 5%, NNVC: -95. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between IBO and NNVC?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.
Closest Rival
Compare NNVC vs SIGA
SIGA is one of the most direct listed alternatives to NNVC.
Segment Rival
Compare IBO vs NVAX
NVAX overlaps with IBO in an adjacent operating segment worth comparing.
Expand Peer Set
Expand With SIGA + GILD
SIGA and GILD are the strongest missing peers across the current compare set.